Pfizer Covid vaccine is far less effective in kids 5 to 11, study finds
Newly rising knowledge recommend the Pfizer-BioNTech Covid vaccine works considerably much less nicely at stopping an infection and hospitalizations in youngsters aged 5 to 11 than it does in these aged 12 to 17 — a discovering that’s elevating questions on whether or not the businesses selected the mistaken dose for the youthful youngsters.
The info, from New York state, present a speedy and substantial decline in safety after vaccination in youngsters within the youthful age group, with efficacy towards infections dropping off extra rapidly and dramatically than the declines seen in youngsters aged 12 to 17. The research additionally discovered a big, however much less steep, decline in safety towards hospitalizations.
The findings, compiled by researchers working for the New York State Division of Well being, have been posted Monday on a preprint server; the research has not but undergone peer assessment.
commercial
The New York findings, together with knowledge from a number of different databases, have been lately introduced to the Covid vaccine work group of the Advisory Committee on Immunization Practices, unbiased vaccine consultants who advise the Facilities for Illness Management and Prevention, sources informed STAT.
The info come on the heels of disappointing outcomes from Pfizer trials of a good decrease vaccine dose in youngsters underneath the age of 5. And they’ll elevate questions on whether or not, in looking for doses that have been each protecting and tolerable in youngsters, the businesses didn’t hit the mark for each age teams.
commercial
Pfizer wouldn’t say whether it is exploring the chance that the dose utilized in youngsters is perhaps too low, however stated it’s “assured within the safety and security” of its Covid-19 vaccine.
“Our updates earlier this 12 months on pursuing a 3-dose schedule for the pediatric inhabitants have been knowledgeable by the effectiveness knowledge for 3 doses of the vaccine for individuals 16 years and older, and the early laboratory knowledge noticed with Delta and different variants of concern, together with Omicron, which recommend that folks vaccinated with three doses of a Covid-19 vaccine might have a better diploma of safety,” it stated in an emailed assertion.
The New York research analyzed well being data for Covid circumstances in youngsters and youths from Dec. 13, 2021 to Jan. 30, 2022, a interval throughout which the Omicron variant was quick changing all different types of the SARS-CoV-2 virus within the nation. Covid vaccines aren’t as protecting towards Omicron as they have been towards earlier variations of the virus, particularly with no booster shot.
The state recorded greater than 850,000 Covid circumstances in adolescents aged 12 to 17 throughout that point, and about 365,000 in youngsters aged 5 to 11.
Over that interval, two-dose vaccine safety towards an infection for teenagers aged 5 to 11 declined from 68% to 12%; the vaccine’s effectiveness at stopping hospitalization declined from 100% to 48%.
However two-dose safety towards an infection for kids aged 12 to 17 solely dropped from 66% to 51%, and safety towards hospitalization from 85% to 73%.
“Our knowledge help vaccine safety towards extreme illness amongst youngsters 5-11 years, however recommend speedy lack of safety towards an infection, within the Omicron variant period,” the researchers wrote. “Ought to such findings be replicated in different settings, assessment of the dosing schedule for kids 5-11 years seems prudent.”
The grownup Pfizer routine — utilized in anybody aged 12 and older — is 2 doses of 30 micrograms apiece, given 21 days aside. Youngsters 5 to 11 years previous obtain a dose that’s one-third that measurement, two doses of 10 micrograms apiece. And in research of youngsters underneath 5, the dose is additional diminished, with the kids aged 6 months to 4 years getting two 3-microgram doses. The vaccine shouldn’t be but approved to be used in youngsters underneath 5.
In December, Pfizer introduced that two doses of the vaccine in youngsters underneath 5 had not generated the identical degree of antibodies as was seen after two doses in individuals 16 to 25, which was getting used as a proxy for cover. It stated it could give the kids underneath 5 a 3rd dose to see if that achieved the required degree of safety.
However then as Omicron circumstances spiked throughout the nation, the Meals and Drug Administration revealed it was contemplating a rolling authorization for the vaccine for kids underneath age 5, permitting dad and mom to begin vaccinating their youngsters whereas ready for the third dose. The rationale was that the risk-benefit equation had shifted with Omicron.
A gathering of the FDA’s vaccine advisers, the Vaccines and Associated Organic Merchandise Advisory Committee, was scheduled for mid-February. However earlier than the group might meet the FDA and Pfizer introduced the plan was on maintain. The plan is now to attend for the third-dose outcomes earlier than contemplating authorization on this age group.
